(Q47692868)

4 February 2018

title

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease (English)

1 reference

4 February 2018

0 references

Shoji M

1 reference

4 February 2018

Matsubara E

1 reference

4 February 2018

Kanai M

1 reference

4 February 2018

Watanabe M

1 reference

4 February 2018

Nakamura T

1 reference

4 February 2018

Tomidokoro Y

1 reference

4 February 2018

Shizuka M

1 reference

4 February 2018

Wakabayashi K

1 reference

4 February 2018

Igeta Y

1 reference

4 February 2018

Ikeda Y

1 reference

4 February 2018

Mizushima K

1 reference

4 February 2018

Amari M

1 reference

4 February 2018

Ishiguro K

1 reference

4 February 2018

Kawarabayashi T

1 reference

4 February 2018

Harigaya Y

1 reference

4 February 2018

Okamoto K

1 reference

4 February 2018

Hirai S

1 reference

4 February 2018

publication date

1 June 1998

1 reference

4 February 2018

Journal of the Neurological Sciences

published in

1 reference

4 February 2018

volume

158

1 reference

4 February 2018

issue

1 reference

4 February 2018

page(s)

134-140

1 reference

4 February 2018

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Modified amyloid beta protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Amyloid beta-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Intracellular generation of amyloid beta-protein from amyloid beta-protein precursor fragment by direct cleavage with beta- and gamma-secretase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Accumulation of beta-amyloid fibrils in pancreas of transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Characterization of apolipoprotein J-Alzheimer's A beta interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900122-1

10.1016/S0022-510X(98)00122-1

7 January 2021

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018